Moreover, we provide support for the feasibility of repurposing pan-ErbB inhibitors as a candidate broad-spectrum antiviral, antiinflammatory, and tissue-protective approach using in vitro and unique ex vivo models of multiple unrelated viral infections and a murine model of VEEV. Here, EGFR is linked to viral infectious disease.